Home › Tarix Granted Orphan Drug Status For TXA127
 

Keywords :   


Tarix Granted Orphan Drug Status For TXA127

2016-02-18 02:28:07| drugdiscoveryonline News Articles

Tarix Orphan LLC today announced that the U.S. Food and Drug Administration has granted Orphan Drug status to the company's lead compound, TXA127, for the treatment of laminin-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). Early-onset LAMA2-related muscular dystrophy occurs in approximately 1 in 30,000 individuals and accounts for between 30 and 40 percent of total cases of congenital muscular dystrophy.

Tags: status drug granted orphan

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
26.06Atlantic Tropical Weather Outlook
26.06Eastern North Pacific Tropical Weather Outlook
26.06XREAL bring Play Store apps to 3D space on XREAL AR glasses
26.06Qwilt reveals live streaming survey results
26.06Rockline Industries Wins WOW Innovation Award
26.06IMS Technologies Expands Calcinate Production Site
26.06Horizon expert 'gave evidence based on informal chats'
26.06Automotive Color by BASF Recognized with Renowned Red Dot Award
More »